Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Beta or fibroblast

Subclass of:

424 - Drug, bio-affecting and body treating compositions

424850100 - LYMPHOKINE

424850400 - Interferon

Patent class list (only not empty are listed)

Deeper subclasses:

Entries
DocumentTitleDate
20110177028INTERFERON-BETA AND/OR LAMBDA FOR USE IN TREATING RHINOVIRUS INFECTION IN THE ELDERLY - Use of interferon-beta (IFN-β) and/or IFN-λ for treating rhinovirus (RV) infection in elderly people, particularly elderly people who are, or have been long-term smokers, especially those who have a clinical history of recurrent RV infections, and may have other medical conditions, such as cardiac or circulation problems, and who are liable to suffer severe complications/high mortality from poor innate ability to fight such a viral infection.07-21-2011
20110200555CONJUGATES OF HYDROXYALKYL STARCH AND A PROTEIN - Conjugates of hydroxyalkyl starch and a protein are provided herein. The conjugates are formed by a convalent linkage between the hydroxyalkyl starch or a derivative of the hydroxyalkyl starch and the protein. Methods of producing the conjugates and the use of the conjugates also are provided herein.08-18-2011
20090123423HYDROXYAMIC ANALOGS AS HEPATITIS C VIRUS SERINE PROTEASE INHIBITOR - The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:05-14-2009
20090035273Combination treatment method with interferon-tau - A method of treating conditions responsive to therapy with interferon-alpha or interferon-beta is provided, where the dose of interferon-alpha or interferon-beta is reduced and a dose of interferon-tau is additionally administered. The method results in efficacious therapy with a reduction in unwanted adverse events.02-05-2009
20080260690Interferon in Influenza - The use of an interferon (IFN) for the manufacture of a medicament for treatment and/or prevention of influenza, preferably avian influenza, is described in the present invention.10-23-2008
20110195049COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS - Described herein are compositions and methods for treating multiple sclerosis. In particular, described herein are compositions that include one or more dimebolins and/or pharmaceutically acceptable salts thereof and methods for using the compositions for treating multiple sclerosis.08-11-2011
20090191154ASSEMBLY AND FOLDING OF FC-INTERFERON-BETA FUSION PROTEINS - Disclosed are Fc-interferon-beta (Fc-IFN-β) fusion proteins and nucleic acid molecules encoding them. The Fc-IFN-β fusion proteins include variants of the interferon-beta (IFN-β) protein that are altered to achieve enhanced biological activity, prolonged circulating half-life and greater solubility. Also disclosed are methods of producing the fusion proteins and methods of using the fusion proteins and/or nucleic acid molecules for treating diseases and conditions alleviated by the administration of interferon-beta.07-30-2009
20100119480Methods for treating multiple sclerosis using antisense oligonucleotides - A method for treating a patient suffering from multiple sclerosis, particularly a relapsing form of multiple sclerosis, comprising periodically administering a pharmaceutical composition comprising a therapeutically effective amount of OLIGONUCLEOTIDE 1 to the patient, thereby treating the patient.05-13-2010
20120244121MODULATORS OF TOLL-LIKE RECEPTOR 7 - The present invention includes therapeutic methods that include the administration of a compound of Formula I or II:09-27-2012
201300782172'-CHLOROACETYLENYL SUBSTITUTED NUCLEOSIDE DERIVATIVES - The present invention relates to 2′-chloroacetylenyl-substituted nucleoside derivatives of the general formula (I):03-28-2013
200802925881-METHYL-BENZO[1,2,4]THIADIAZINE 1-OXIDE DERIVATIVES - The invention is directed to 1-methyl-benzo[1,2,4]thiadiazine 1-oxide derivatives and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.11-27-2008
20090202484MODULATORS OF TOLL-LIKE RECEPTOR 7 - The present application provides for a compound of Formula (I) or (II): or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods that include the administration of such compounds with at least one additional active agent.08-13-2009
20090155211Methods and Compositions for the Treatment of Autoimmune Disorders Using Clofarabine - This invention relates to methods of treating or preventing an autoimmune disorder comprising the administration of clofarabine or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, prodrug or metabolite thereof to a patient in need of such treatment. The invention further relates to methods of treating or preventing an autoimmune disorder comprising the administration of clofarabine or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, prodrug or metabolite thereof and an additional therapeutic agent to a patient in need of such treatment.06-18-2009
20090155210OXIMYL HCV SERINE PROTEASE INHIBITORS - The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof:06-18-2009
20130028867LONG-ACTING INTERFERON BETA FORMULATION USING IMMUNOGLOBULIN FRAGMENT - The present invention relates to a long-acting interferon beta formulation having improved in vivo duration and stability, comprising an interferon beta conjugate that is prepared by covalently linking interferon beta with an immunoglobulin Fc region via a non-peptidyl polymer, and a preparation method thereof. The long-acting interferon beta formulation of the present invention maintains in vivo activity of interferon beta at a relatively high level and remarkably increases the serum half-life thereof, thereby being used for various diseases, for which interferon is efficacious.01-31-2013
20130028866TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND INTERFERON-BETA - This invention provides a method of treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the patient laquinimod as an add-on therapy to or in combination with interferon-β. This invention also provides a package and a pharmaceutical composition comprising laquinimod and interferon-β for treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with interferon-β in treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and interferon-β in the preparation of a combination for treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome.01-31-2013
20130089519Method for Predicting a Therapy Response in Subjects with Multiple Sclerosis - A method is provided for determining the efficacy of interferon-beta (IFN-β) therapy in a subject with multiple sclerosis. One step of the method can include obtaining a biological sample from the subject. After obtaining the biological sample, the expression level of at least one interferon-regulated gene (IRG) and/or variant thereof can be determined. Increased or decreased expression of the at least one IRG and/or variant thereof as compared to a control may indicate that the subject will respond poorly to IFN-β therapy.04-11-2013
20090304629MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, II or III, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:12-10-2009
20090104150Polymer conjugates of interferon Beta-1a and uses - An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as compared to non-conjugated interferon-beta-1a. The conjugates of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications.04-23-2009
20090068143ORALLY EFFECTIVE CANNABINOID ANALOGS - The present invention relates to orally effective ligands of the peripheral cannabinoid receptor CB03-12-2009
20130064792THERAPY FOR INFLUENZA LIKE ILLNESS - An agent selected from: (a) interferon-β (IFN-β); (b) an agent that increases IFN-β expression; or (c) a polynucleotide which is capable of expressing (a) or (b); for use in the treatment of individuals with lower respiratory tract illness that has developed during or following an established ILI, wherein said treatment is by airway delivery of said medicament.03-14-2013
20090047250Methods for treating or preventing neuroinflammation or autoimmune diseases - Disclosed herein are ribonucleotide reductase inhibitors, compositions comprising ribonucleotide reductase inhibitors, and methods for treating and/or preventing autoimmune diseases and neuroinflammatory diseases with the ribonucleotide reductase inhibitors.02-19-2009
20090047249Modulators of toll-like receptor 7 - The present application includes a compound of Formula I or II:02-19-2009
20100074864METHODS AND KITS FOR PREDICTING PROGNOSIS OF MULTIPLE SCLEROSIS - Provided are methods and kits for predicting the prognosis of a subject diagnosed with multiple sclerosis by determining the expression level of polynucleotides which are differentially expressed between subjects diagnosed with multiple sclerosis and having good or poor clinical outcome. Also provided are methods and kits for selecting a treatment regimen of a subject diagnosed with multiple sclerosis.03-25-2010
20120237479METHOD FOR REDUCING FLU-LIKE SYMPTOMS ASSOCIATED WITH INTRAMUSCULAR ADMINISTRATION OF INTERFERON USING A FAST TITRATION ESCALATING DOSING REGIMEN - The present invention provides a method for treating multiple sclerosis (MS), and for reducing flu-like symptoms associated with administration of an interferon to a patient with MS. The method involves intramuscularly administering the interferon to the MS patient according to an escalating dosing regimen in weeks 1 to 3, and a full therapeutically effective dose of interferon in week 4. In one embodiment of the invention, the escalating dosing regimen comprises administering one quarter of the therapeutically effective dose in week 1, half of the therapeutically effective dose in week 2, and three-quarters of the therapeutically effective dose in week 3. Also provided are titration packages for enabling compliance with a regimen of changing dosage of an interferon over a period of time.09-20-2012
20120237478MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS - The present application provides for a compound of Formula IV,09-20-2012
201102935642-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES - This invention relates to compounds of Formula (I) as Pi3k inhibitors for treating autoimmune diseases, inflammatory disorders, multiple sclerosis and other deseases like cancers.12-01-2011
20110280830Albumin Fusion Proteins - The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.11-17-2011
20110280832EOTAXIN-2 (CCL24) INHIBITORS IN INFLAMMATORY, AUTOIMMUNE, AND CARDIOVASCULAR DISORDERS - The presently described subject matter is based on the finding that inhibition of eotaxin-2 by polyclonal or monoclonal antibodies, has a significant protective effect in animal models of inflammatory diseases such as rheumatoid arthritis, experimental autoimmune encephalomyelitis (EAE), colitis, diabetes, and atherosclerosis. Thus, provided are pharmaceutical compositions including specific anti-eotaxin 2 antibodies for use alone or in combination with other therapeutic agents in the treatment of inflammatory, autoimmune and cardiovascular diseases. Also provided are specific anti-eotaxin-2 monoclonal antibodies, and methods of treatment utilizing such antibodies.11-17-2011
20110280831COMBINATIONS COMPRISING METHOTREXATE AND DHODH INHIBITORS - The present invention provides a combination which comprises (a) methotrexate and (b) a non-hepatotoxic DHODH inhibitor of formula (I): wherein: R11-17-2011
20090123424Methods of protein purification and recovery - Improved methods for purification and recovery of interferon-beta (IFN-β) and compositions comprising substantially monomeric IFN-β are provided. In one purification method, substantially purified IFN-β or variant thereof is precipitated and then dissolved in a guanidine hydrochloride (HCl) solution. Renaturation of the protein occurs by dilution with a suitable buffer. A similar purification method absent the precipitation step is also provided. Following renaturation of the IFN-β residual guanidine HCl is removed by diafiltration or dialysis with a pharmaceutically acceptable buffer to prepare pharmaceutical compositions comprising substantially monomeric IFN-β.05-14-2009
20100239531STABLE LIQUID INTERFERON FORMULATIONS - Liquid interferon compositions having a pH between 4.0 and 7.2 are described. The compositions comprise interferon-beta and a stabilizing agent at between about 0.3% and 5% by weight which is an amino acid selected from the group consisting of acidic amino acids, arginine and glycine. If needed, salt is added to provide sufficient ionic strength. The liquid composition has not been previously lyophilized or previously cavitated. The liquid is preferably contained within a vessel having at least one surface in contract with the liquid that is coated with a material inert to adsorption of interferon-beta. A kit for parenteral administration of a liquid interferon formulation and a method for stabilizing liquid interferon compositions are also described.09-23-2010
20100254943AMINO ACID SUBSTITUTED MOLECULES - The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also relate to kits for identifying, modifying and producing modified target molecules described herein.10-07-2010
20100272683HETEROCYCLYLAMINOALKYL SUBSTITUTED BENZIMIDAZOLES - Heterocyclylaminoalkyl Substituted Benzimidazoles Inhibitors of RSV replication of formula (I): The salts and stereochemically isomeric forms thereof, wherein Q is hydrogen, C1-6alkyl optionally substituted with a heterocycle or Q is C1-6alkyl substituted with both —OR4 and a heterocycle; wherein said heterocycle is oxazolidine, thiazolidine, 1-oxo-thiazolidine, 1,1-dioxothiazolidine, morpholinyl, thiomorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxothiomorpholinyl, hexahydrooxazepine, hexahydrothiazepine, 1-oxo-hexahydrothiazepine, 1,1-dioxo-hexahydrothiazepine, pyrrolidine, piperidine, homopiperidine, piperazine; which heterocyle may be substituted with 1-2 substituents; each Alk is C1-6alkanediyl; R1 is Ar or optionally substituted piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, furanyl, tetrahydrofuranyl, thienyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, isothiazolyl, pyrazolyl, isoxazolyl, oxadiazolyl, quinolinyl, quinoxalinyl, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, pyridopyridyl, naphthiridinyl, 1H-imidazo[4,5-b]pyridinyl, 3H-imidazo[4,5-b]pyridinyl, imidazo[1,2-a]pyridinyl or 2,3-dihydro-1,4-dioxino[2,3-b]pyridyl; R3 is hydroxyC1-6alkyl, C1-6alkoxyC1-6alkyl, cyanoC1-6alkyl, aminocarbonyl-C1-6-alkyl, mono- or di(C1-6alkyl)aminocarbonyl-C1-6-alkyl, carboxyl-C1-6-alkyl, C1-6alkoxycarbonyl-C1-6 alkyl; R2, R4 and R5 are hydrogen or C1-6alkyl; Het is pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, furanyl, tetrahydrofuranyl, thienyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, isothiazolyl, pyrazolyl, isoxazolyl, oxadiazolyl, quinolinyl, quinoxalinyl, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, pyridopyridyl, naphthiridinyl, 1H-imidazo[4,5-b]-pyridinyl, 3H-imidazo[4,5-b]pyridinyl, imidazo[1,2-a]pyridinyl and 2,3-dihydro-1,4-dioxino[2,3-b]pyridyl; Ar is optionally substituted phenyl; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I).10-28-2010
20090202485HETEROARYL-CONTAINING TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:08-13-2009
20110286968CD40 AGONIST ANTIBODY /TYPE 1 INTERFERON SYNERGISTIC ADJUVANT COMBINATION, CONJUGATES CONTAINING AND USE THEREOF AS A THERAPEUTIC TO ENHANCE CELLULAR IMMUNITY - A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided.11-24-2011
20120014917METHODS OF TREATING HIV PATIENTS WITH ANTI-FIBROTICS - The invention relates to methods of treating patients infected with human immunodeficiency virus (HIV) with a therapeutic that has anti-fibrotic effects, for example, pirfenidone and analogs thereof.01-19-2012
20110142801PROTEASE RESISTANT MODIFIED INTERFERON-BETA POLYPEPTIDES AND THEIR USE IN TREATING DISEASES - Protease resistant modified interferon-beta polypeptides, pharmaceutical compositions and methods of treatment by administering the compositions are provided. The modified interferon-beta polypeptides are orally available; hence pharmaceutical compositions formulated for oral administration also are provided.06-16-2011
20110300105Dimeric Alpha Interferon PEGylated Site-Specifically Shows Enhanced and Prolonged Efficacy in Vivo - The present invention concerns methods and compositions for forming PEGylated complexes of defined stoichiometry and structure. In preferred embodiments, the PEGylated complex is formed using dock-and-lock technology, by attaching a therapeutic agent to a DDD sequence and attaching a PEG moiety to an AD sequence and allowing the DDD sequence to bind to the AD sequence in a 2:1 stoichiometry, to form PEGylated complexes with two therapeutic agents and one PEG moiety. In alternative embodiments, the therapeutic agent may be attached to the AD sequence and the PEG to the DDD sequence to form PEGylated complexes with two PEG moieties and one therapeutic agent. In more preferred embodiments, the therapeutic agent may comprise any peptide or protein of physiologic or therapeutic activity, preferably a cytokine, more preferably interferon-α2b. The PEGylated complexes exhibit a significantly slower rate of clearance when injected into a subject and are of use for treatment of a wide variety of diseases.12-08-2011
20080286233PIPERIZINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:11-20-2008
201000550722-OXO-1,2-DIHYDRO-QUINOLINE MODULATORS OF IMMUNE FUNCTION - The present invention relates to new 2-oxo-1,2-dihydro-quinoline modulators of immune function, pharmaceutical compositions thereof, and methods of use thereof.03-04-2010
20090130059TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, II, III or IV, or pharmaceutically acceptable salts, esters, or prodrugs thereof:05-21-2009
201001194815,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS - The invention is directed to 5,6-dihydro-1H-pyridin-2-one compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.05-13-2010
20100119482Treatment of Conditions Through Modulation of the Autonomic Nervous System During at Least One Predetermined Menstrual Cycle Phase - Methods are provided for treating a subject for a condition. In accordance with the subject methods, at least a portion of a subject's autonomic nervous system is modulated during at least one predetermined phase of the subject's menstrual cycle to alter the parasympathetic activity/sympathetic activity ratio in a manner that is effective to treat the subject for the condition. The subject methods find use in the treatment of a variety of different conditions, including various disease conditions, that increase in severity and/or occurrence during one or more phases of the menstrual cycle. Also provided are systems and kits for use in practicing the subject methods.05-13-2010
20090311216RECOMBINANT INTERFERON-BETA WITH ENHANCED BIOLOGICAL ACTIVITY - Human interferon-β protein analogs in which the asparagine at position 25, numbered in accordance with native human interferon-β, is recombinantly replaced with an aspartate residue exhibit a biological activity of human interferon-β (e.g. IFN-β 1b) at an increased level relative to IFN-β 1b. These analogs are obtained by introducing a gene coding for Asp25 IFN-β into a cell and expressing the recombinant protein. The resulting IFN-β protein analog is suitable for large scale manufacturing for incorporation in HA-containing or HA-free therapeutics for treatment of diseases including multiple sclerosis. A reduced Lys endoproteinase-C peptide map technique that produces a fingerprint profile for proteins using an enzymatic digest followed by RP-HPLC is also useful in quality control as an ID test for the IFN-β protein analog products.12-17-2009
20090087411Long-acting interferons and derivatives thereof and methods thereof - A polypeptide and polynucleotides encoding same comprising carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to an IFN protein are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed.04-02-2009
20110200557NEW 2-AMIDOTHIADIAZOLE DERIVATIVES - The present disclosure relates to 2-amidothiadiazole derivatives of formula (I) as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the S1P1 receptors.08-18-2011
20120107277USE OF THE COMBINATION OF TERIFLUNOMIDE AND INTERFERON BETA FOR TREATING MULTIPLE SCLEROSIS - This invention is related to the use of the combination of teriflunomide and interferon beta thereof, for the preparation of a medicament for use in treating multiple sclerosis.05-03-2012
20090263355DEAMIDATED INTERFERON-BETA - Interferon-β protein analogs in which the asparagine at position 25, numbered in accordance with native interferon-β, is deamidated exhibit a biological activity of native human interferon-β at an increased level and do not require HA for protein stabilization. The deamidated product is suitable for large scale manufacturing for incorporation in HA-containing or HA-free therapeutics for treatment of diseases including multiple sclerosis. An endoproteinase-C peptide map technique that produces a fingerprint profile for proteins using an enzymatic digest followed by RP-HPLC is also useful in quality control as an ID and/or quantitative test for the deamidated products.10-22-2009
20090098086THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS - The invention relates to thienopyrimidine and pyrazolopyrimidine compounds of the Formulas (Ia) and (IIa),04-16-2009
20110200556CHEMOPREVENTION OF HEAD AND NECK SQUAMOUS CELL CARCINOMAS - Disclosed is a method for preventing the development of head and neck squamous cell carcinoma (HNSCC) in a mammal who is at risk for developing such carcinoma comprising administering an effective amount of a mammalian target of rapamycin (mTOR) inhibitor to the mammal. An example of such inhibitor is rapamycin.08-18-2011
20090274657DIFLUOROMETHYL-CONTAINING MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof:11-05-2009
20090274658Tight Junction Modulating Peptides for Enhanced Mucosal Delivery of Therapeutic Compounds - Compositions and methods are provided that include a biologically active agent and a permeabilizing agent effective to enhance mucosal delivery of the biologically active agent in a mammalian subject, in which the permeabilizing peptide is a tight junction modulating peptide (TJMP), a TJMP analogue, a conjugate of a TJMP, a conjugate of a TJMP analogue, or complexes thereof. The permeabilizing agent reversibly enhances mucosal epithelial paracellular transport, typically by modulating epithelial junctional structure and/or physiology at a mucosal epithelial surface in the subject.11-05-2009
20110171177Compositions and Methods for Inhibiting Entry of a Hepatic Virus - The present invention embraces Niemann-Pick C1-like 1 protein antagonists and agents that inhibit hepatic virus infection for use in the prevention and treatment of a hepatic virus infection.07-14-2011
20080292589NOVEL HETEROCYCLIC SUBSTITUTED PYRIDINE OR PHENYL COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY - The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1:11-27-2008
20090104151SMAC MIMETIC DIMERS AND TRIMERS USEFUL AS ANTI-CANCER AGENTS - The invention provides small molecule mimics of the Smac peptide that are dimer-like or trimer-like compounds having two or three amide-containing domains connected by a linker. These compounds are useful to promote apoptosis. The invention includes pharmaceutical compositions comprising such compounds and methods to use them to treat conditions including cancer and autoimmune disorders.04-23-2009
20090285781 Medicament and a method of treating a pathological syndrome - A medicament based on antibodies contains an activated form of monoclonal, polyclonal, or natural antibodies to interferon in low or ultra-low doses prepared by multiple consecutive dilutions and exposure to external factors, preferably in accordance with homeopathic technology. In order to obtain antibodies, human or heterologous interferon alpha, beta, or gamma, including recombinant interferon, is used; a mixture of various, mostly centimal, homeopathic dilutions being employed. A method of treating a pathologic syndrome, whose formation is affected by interferon, consists in the use of activated forms of antibodies to interferon alpha, beta, or gamma in low or ultra-low doses obtained by multiple consecutive dilutions and exposure to external factors.11-19-2009
20090041722INDOLE INDANE AMIDE COMPOUNDS USEFUL AS CB2 AGONISTS AND METHOD - Indole indane amides which are CB2 agonists are provided which have the structure02-12-2009
20090297478Methods and Compositions for the Treatment of Lupus Using Clofarabine - This invention relates to methods of treating or preventing lupus comprising the administration of clofarabine or a pharmaceutically acceptable salt, hydrate, solvate or clathrate thereof to a patient in need of such treatment. The invention further relates to methods of treating or preventing lupus comprising the administration of clofarabine or a pharmaceutically acceptable salt, hydrate, solvate or clathrate thereof and an additional therapeutic agent to a patient in need of such treatment.12-03-2009
20090297477Estriol Therapy for Autoimmune and Neurodegenerative Disease and Disorders - The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, including post-partum auto immune diseases) and more particularly. Most preferably the invention uses estrogens, estranges, estriol or estrogen receptor active agents to prevent or ameliorate clinical symptoms of these ThI-mediated (cell-mediated) autoimmune diseases known to either have an initial onset following the birth of a child or which are exacerbated in patients in the post12-03-2009
20100129321DIARYL UREA FOR TREATING VIRUS INFECTIONS - The present invention relates to pharmaceutical compositions for treating virus infections and/or diseases caused thereby comprising 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide optionally combined with at least one additional therapeutic agent.05-27-2010
20080274082OXIMYL HYDROXYAMIC ANALOGS AS HEPATITIS C VIRUS PROTEASE INHIBITOR - The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:11-06-2008
20080286234Method for treating demyelinating diseases - A method for treating demyelinating diseases such as MS comprised of administering to an individual afflicted with a demyelinating disease a medicament that induces prolactin secretion. Prolactin secretion stimulates oligodendrocyte precurser cells, which remyelinate demyelinated nerve cells. The medicament is administered at a dosage sufficient to induce prolactin secretion resulting in a hyperprolactinemia. Estrogen, estradiol, estriol, histamine H11-20-2008
20080292590Soluble Receptors and Methods for Treating Autoimmune or Demyelinating Diseases - The present invention relates to novel therapeutic protein useful in the treatment of diseases, in particular in human subjects. The results of the inventor strongly support the use of soluble IL-18Rα in the treatment of diseases such as autoimmune or demyelinating disease, in particular Multiple Sclerosis (MS). Accordingly, the invention provides soluble IL-18Rα for use in the treatment of autoimmune or demyelinating disease, in particular MS. The invention also provides methods of treating, preventing or ameliorating the symptoms of autoimmune or demyelinating disease, in particular MS, in a subject, preferably a human subject, by administering a therapeutically effective amount of said soluble IL-18Rα to the subject.11-27-2008
20080292586Method and Use of Interferon Compositions For the Treatment of Avian Influenza - The present invention provides methods and uses for an interferon composition in the treatment of avian influenza. Transmission of avian influenza virus H5N1 to humans has been shown to be highly pathogenic. The present invention provides for methods of treatment that provide a broad spectrum, first line defense against avian influenza infection in humans. The methods of the present invention can be further extended to treat strains of avian influenza viruses that have resulted from antigenic drift, this potentially resulting in avian influenza based virus which is highly pathogenic and transmissible between humans.11-27-2008
20080292587OXIMYL DIPEPTIDE HEPATITIS C PROTEASE INHIBITORS - The present invention discloses compounds of formulae I, or pharmaceutically acceptable salts, esters, or prodrugs thereof:11-27-2008
20100183554Anti-CD3 Antibodies and Methods of Use Thereof - The present invention is related to antibodies directed to the antigen CD3 and uses of such antibodies. In particular, the present invention provides fully human monoclonal antibodies directed to CD3. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.07-22-2010
20080311079Inhibitors of serine proteases, particularly HCV NS3-NS4A protease - The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.12-18-2008
20080317712ARYLPIPERIDINYL AND ARYLPYRROLIDINYL TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:12-25-2008
20080267917N-FUNCTIONALIZED AMIDES AS HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to functionalized amides of Formula I or Formula II, including pharmaceutically acceptable salts, esters, or prodrugs thereof which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.10-30-2008
20080267916CYCLIC P3 TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:10-30-2008
20110268699METHODS FOR TREATING MULTIPLE SCLEROSIS USING TETRACYCLIC PYRAZINOINDOLES - Methods and pharmaceutical compositions for treating multiple sclerosis are described. The methods and pharmaceutical compositions include a therapeutically effective amount of one or more tetracyclic pyrazinoindoles, and/or pharmaceutically acceptable salts thereof.11-03-2011
20090053176New Combination 937 - The present invention related to a combination of (a) a compound which is a MPO inhibitor or a pharmaceutically acceptable salt thereof and (b) a compound or a pharmaceutically acceptable salt thereof, which is used in the treatment and/or prevention of PD or Multiple Sclerosis. The invention further relates to pharmaceutical compositions comprising said combination and to methods of treating Neuroinflammatory and Neurodegenerative Disorder(s), such as PD and Multiple Sclerosis in mammals by administrating said combination. The invention further relates to a kit comprising the combination and use of said kit in treatment of Neuroinflammatory Disorder(s).02-26-2009
20120195855METHODS FOR UP-REGULATING ANTIGEN EXPRESSION IN TUMORS - The invention provides methods of modulating tumor antigen associated (TAA) expression, and methods of modulating TAA expression in order to treat a tumor. More particularly, the invention provides methods of increasing an immune response against a tumor cell. Methods include administering to a subject with a tumor an amount of IFN-β receptor agonist and tumor associated antigen (TAA) sufficient to increase an immune response against the tumor cell.08-02-2012
20090180983BICYCLIC, C5-SUBSTITUTED PROLINE DERIVATIVES AS INHIBITORS OF THE HEPATITIS C VIRUS NS3 PROTEASE - The present invention relates to compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof:07-16-2009
20090123425MACROCYCLIC, PYRIDAZINONE-CONTAINING HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, II, or III, or pharmaceutically acceptable salts, esters, or prodrugs thereof:05-14-2009
20090041721ARYLALKOXYL HEPATITIS C VIRUS PROTEASE INHIBITORS - The present invention discloses compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof:02-12-2009
20090180984MACROCYCLIC OXIMYL HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof:07-16-2009
20120070415AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS - Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof. Examples of viral infections include a respiratory syncytial viral (RSV) and influenza infection.03-22-2012
20090136450THERAPY FOR NEUROLOGICAL DISEASES - The present invention relates to compositions and methods for treating neurological diseases in a subject. More specifically, the invention relates to combination therapies for treating such diseases, using a c-kit inhibitor and a neuroactive compound. The invention may be used against a variety of demyelinating diseases, including multiple sclerosis, in any mammalian subject, particularly human subjects, and at various stages of disease progression.05-28-2009
20130216498IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS - New imidazopyridine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).08-22-2013
20080317711Treatment of Optic Neuritis - The present invention provides a method for treating a patient having demyelinating optic neuritis (DON) comprising the sequential or simultaneous administration of a steroid compound and an interferon-beta protein. It is found that early, aggressive treatment of IFN-b is beneficial in such a treatment regimen, for example where the interferon-beta protein is administered at a cumulative weekly dose of more than 12 MIL). The method according to the invention is particularly suitable and beneficial for treatment of patients having early stage DON. In particular, the DON that will benefit from being treated according to the present invention may be in subclinical stage.12-25-2008
20090081162METHOD FOR DOWNREGULATING AN IMMUNE REACTION - Ongoing pathogenic immune reactions and the severity of an incipient or prospective immune reaction may be downregulated or reduced by locally administering Type I interferon at a site remote from the ongoing, incipient or prospective immune reaction. The amount of interferon to be administered is that which is effective to induce trafficking of antigen-presenting cells to the site of interferon administration, and away from the site of the immune reaction. It is administered in the course of the ongoing immune reaction, or concurrently with the provocation of an immune reaction.03-26-2009
20090081163CLADRIBINE REGIMEN FOR TREATING MULTIPLE SCLEROSIS - The present invention is related to the use of Cladribine for the preparation of a pharmaceutical formulation for the treatment of multiple sclerosis, especially relapsing-remitting multiple sclerosis or early secondary progressive multiple sclerosis, wherein the preparation is to be orally administered and wherein re-treatments are possible.03-26-2009
20090208455 Method for Treating Polyglutamine Expansion Neurodegenerative Diseases - The present invention relates to use of an inducer of Promyelocytic Leukemia protein (PML) expression, and especially PML IV for the manufacture of a medicament intended for the treatment of polyglutamine expansion neurodegenerative diseases. More specifically, the present invention relates to the use of an interferon polypeptide for the manufacture of a medicament intended for the treatment of polyglutamine expansion neurodegenerative diseases.08-20-2009
20090098085TETRAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, II, III or IV, or pharmaceutically acceptable salts, esters or prodrugs thereof:04-16-2009
20090202486DIFLUORINATED TRIPEPTIDES AS HCV SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:08-13-2009
20100150868Methods of Individually Optimizing Treatment for an Inflammation Associated Disease - A method of individually optimizing a treatment for an inflammation associated disease is provided. The method comprising contacting each of identical white blood cell samples of a subject in need thereof with a different pharmaceutical agent of a plurality of pharmaceutical agents for the inflammation associated disease, so as to allow elicitation of an anti-inflammatory activity in the white blood cell samples; assaying the anti-inflammatory activity in the white blood cell samples; and identifying a pharmaceutical agent of the plurality of pharmaceutical agents eliciting a strongest anti-inflammatory activity, the pharmaceutical agent being the individually optimized treatment for the inflammation associated disease, wherein when the inflammation associated disease is multiple sclerosis the white blood cell samples are inflamed white blood cell samples. Methods of treating an inflammation associated disease are also described.06-17-2010
20100183553Composition and Methods for Affecting Metallocorrinoid Uptake - The present invention is directed to compositions and methods for affecting metallocorrinoid uptake. The compositions and methods of the present invention are particularly useful in enhancing the uptake or availability of biologically active metallocorrinoids (e.g. cobalamin and its analogs). The present invention is particularly useful in the treatment or prevention of conditions that result from low expression or activity of proteins involved in the processing of metallocorrinoids, as well as in conditions which would benefit from enhanced uptake or availability of cobalamin or its biologically active analogs of cobalamin (e.g. cobalamin drug conjugates).07-22-2010
201001835521-[2-AMINO-3-(SUBSTITUTED ALKYL)-3H-BENZIMIDAZOLYLMETHYL]-3-SUBSTITUTED-1,3-DIHYDRO-BENZOIMIDAZOL-2- -ONES AND STRUCTURAL ANALOGS - Inhibitors of RSV replication of formula (I) which can be represented by formula (I)07-22-2010
20100260716COMPOUNDS FOR TREATING DEMYELINATION CONDITIONS - Therapeutic methods, therapeutic combinations and pharmaceutical compositions provided herein are useful for inhibiting demyelination, for delaying the clinical onset of a demylination condition, for inhibiting progression and/or reducing frequency of relapse of a demylination condition, and/or enhancing physical ability of a human subject having a demylination condition. Lacosamide is one of the active compounds.10-14-2010
20110059045PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT - The invention relates to therapeutic compositions for the treatment of cancer and, more specifically, compositions containing an agonist ligand for receptor 4-1BB and a type-1 interferon, the simultaneous or sequential delivery of which results in a synergic antitumour effect in relation to the individual delivery of any of the components. The invention also relates to the therapeutic uses of the combinations of the invention for the treatment of cancer. The invention further relates to polynucleotides that code for compounds, vectors and cells containing same, as well as to the use thereof for the treatment of cancer.03-10-2011
20100239530IFNAR2 MUTANTS, THEIR PRODUCTION AND USE - The present invention relates to mutant polypeptides of the beta chain of the type I IFN receptor (IFNAR2 mutant) with enhanced affinity for IFNβ as compared to the wild type protein for prolonging the effect of IFNβ in vivo.09-23-2010
20100203016PREGNANCY HORMONE COMBINATION FOR TREATMENT OF AUTOIMMUNE DISEASES - The present invention relates to pregnancy hormone combinations and methods of treatment for autoimmune diseases having at least two hormonal components, a pregnancy hormone (such as estriol), and a gestagen (such as levonorgestrel or norethindrone) thereby providing for the continuous, uninterrupted administration of pregnancy hormones for the treatment for autoimmune disorders, such as multiple sclerosis.08-12-2010
20110236350ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES - The present invention relates to treatment of neurological diseases such as multiple sclerosis (MS) and Alzheimer's disease, using an estrogen receptor beta (ERβ) ligand in combination with a standard, anti-inflammatory agent.09-29-2011
20100221219COMPOSITIONS FOR TREATING MULTIPLE SCLEROSIS - Compositions comprising Tr1 cells directed to a multiple sclerosis associated antigen and methods for treating multiple sclerosis.09-02-2010
20080267918QUINOXALINYL DIPEPTIDE HEPATITIS C VIRUS INHIBITORS - The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:10-30-2008
20100297076TARGETED INTERFERON DEMONSTRATES POTENT APOPTOTIC AND ANTI-TUMOR ACTIVITIES - This invention provides novel chimeric moieties that show significant efficacy against cancers. In certain embodiments the chimeric moieties comprise a targeting moiety attached to an interferon. In certain embodiments, the chimeric moieties comprise fusion proteins where an antibody that specifically binds to a cancer marker is fused to interferon alpha (IFN-α).11-25-2010
20090110661Novel Gene Therapy Approach For Treating The Metabolic Disorder Obesity - The present application relates to novel methods for treating obesity. Some aspects pertain to the use of gene therapy to treat diseases related to metabolic dysfunction, such as diabetes, obesity, high blood pressure, and atherogenic dyslipidemia. The present application also pertains to the use of vectors such as a recombinant adeno-associated virus (AAV) to deliver a gene that can increase or decrease expression of a therapeutic protein of interest, e.g., in cells in a specific region of the brain associated with metabolic dysfunction. The present application also discloses the use of vectors such as a recombinant adeno-associated virus for the delivery of small interference RNA's (siRNAs) capable of decreasing expression of a deleterious protein involved in the disorder. Other related aspects, including compositions related to such methods, are also disclosed.04-30-2009
20110129445COMBINATIONS COMPRISING METHOTREXATE AND DHODH INHIBITORS - The present disclosure relates to combinations comprising (a) methotrexate, and (b) a DHODH inhibitor and their uses.06-02-2011
20110123496BISMACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of formula Ia or Ib or pharmaceutically acceptable salts, esters, or prodrugs thereof:05-26-2011
20090074720METHODS FOR DECREASING IMMUNE RESPONSE AND TREATING IMMUNE CONDITIONS - The present invention relates to compositions and methods for decreasing an immune response in an animal comprising administering to said animal an agent that binds a bioactive lipid and reduces the effective concentration of said bioactive lipid. Also provided are methods for treating diseases or conditions, including autoimmune disorders, which are characterized by an aberrant, excessive or undesired immune response. The methods of the invention utilize agents that bind bioactive lipids and are capable of decreasing the effective concentration of the bioactive lipid. In some embodiments, the agent is a monoclonal antibody that is reactive against sphingosine-1-phosphate (S1P) or lysophosphatidic acid (LPA).03-19-2009
20090214472Interferon-beta polymer conjugates - Biologically-active, interferon-beta 1b-polymer conjugate compositions are disclosed. The polymer portion is preferably a polyalkylene oxide polymer having a molecular weight of at least about 12 kDa. Methods of making and using the same are also disclosed.08-27-2009
20110008290METHOD FOR PREDICTING THE THERAPEUTIC RESPONSIVENESS OF PATIENTS TO A MEDICAL TREATMENT WITH AN INTERFERON - A method for predicting a response of a patient to a medical treatment with interferon, wherein the method includes detecting the allele identity of a polymorphism in the OAS1 gene in a nucleic acid sample previously obtained from the patient, and optionally detecting the allele identity01-13-2011
20110008289HYPERGLYCOSYLATED POLYPEPTIDE VARIANTS AND METHODS OF USE - The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more native or non-native glycosylation sites. The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more native or non-native glycosylation sites, as well as erythropoietin and darbepoetin alfa, each of which are linked to a penetrating peptide that facilitates translocation of a substance across a biological barrier as well as pharmaceutical compositions, including oral formulations, of the same. The present invention further provides oral formulations of hyperglycosylated or protease-resistant, hyperglycosylated polypeptide variants, which polypeptide variants lack at least one protease cleavage site found in a parent polypeptide, and thus exhibit increased protease resistance compared to the parent polypeptide, which polypeptide variants further include (1) a carbohydrate moiety covalently linked to at least one non-native glycosylation site not found in the parent protein therapeutic or (2) a carbohydrate moiety covalently linked to at least one native glycosylation site found but not glycosylated in the parent protein therapeutic. The present invention further provides compositions, including oral pharmaceutical compositions, comprising the synthetic Type I interferon receptor polypeptide agonist, the hyperglycosylated polypeptide variant, or the hyperglycosylated, protease-resistant polypeptide variant. The present invention further provides containers, devices, and kits comprising the synthetic Type I interferon receptor polypeptide agonist, the hyperglycosylated polypeptide variant, or the hyperglycosylated, protease-resistant polypeptide variant. The present invention further provides therapeutic methods involving administering an effective amount of an oral pharmaceutical composition comprising a synthetic Type I interferon receptor polypeptide agonist, a hyperglycosylated polypeptide variant, or a hyperglycosylated, protease-resistant polypeptide variant to an individual in need thereof.01-13-2011
20090035274TREATMENT AND/OR PREVENTION OF CANCER AND/OR ARTHRITIS - The invention relates to the use of INSP163 for treatment and/or prevention of cancer and/or musculoskeletal/connective tissue disorder, in particular of lung cancer and/or osteoarthritis. Combinations of INSP163 with an interferon, a TNF antagonist or a further anti-cancer or anti-arthritis agent are also within the present invention.02-05-2009
20090035271TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, II, III or IV, or pharmaceutically acceptable salts, esters, or prodrugs thereof:02-05-2009
20110033420MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof:02-10-2011
20110117056DIAGNOSIS AND TREATMENT OF DISEASES OR DISORDERS ASSOCIATED WITH XENOTROPIC MURINE LEUKEMIA VIRUS - Methods of detecting, diagnosing, monitoring or managing an XMRV-related neuroimmune disease such as chronic fatigue syndrome or XMRV-related lymphoma such as mantle cell lymphoma in a subject are disclosed. These methods comprise determining presence, absence or quantity an XMRV immunopeptide, an XMRV antigen, or an XMRV nucleic acid in a sample from a subject. Therapeutic methods of treatment with anti-retroviral agents are also disclosed. Further disclosed are assays for testing compounds having activity against XMRV.05-19-2011
200903112173-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES - The invention relates to 3-substituted-1H-indole compounds of the Formula I:12-17-2009
20100221218Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation - The present invention provides tumor cell preparations for use as models of the EMT process for use in the identification of anti-cancer agents, wherein said tumor cell preparations comprise cells of the epithelial tumor cell line H1650, which are stimulated by receptor ligands to induce EMT, or which have been engineered to inducibly express a protein that stimulates EMT. The present invention also provides methods of identifying potential anti-cancer agents by using such tumor cell preparations to identify agents that inhibit EMT, stimulate MET, or inhibit the growth of mesenchymal-like cells. Such agents should be particularly useful when used in conjunction with other anti-cancer drugs such as EGFR and IGF-1R kinase inhibitors, which appear to be less effective at inhibiting tumor cells that have undergone an EMT.09-02-2010
20100015092QUINOXALINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:01-21-2010
201000347735,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS - The invention is directed to 5,6-dihydro-1H-pyridin-2-one compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.02-11-2010
20090035272Pyridazinonyl Macrocyclic Hepatitis C Serine Protease Inhibitors - The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.02-05-2009
20110150834CRTH2 MODULATORS - Modulators of CRTH2, particularly antagonists of CRTH2, that are useful for treating various disorders, including asthma and respiratory disorders are disclosed. The compounds fall within a genus described by formula I:06-23-2011
20110081316PYRAZOLE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE - The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3Kγ. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.04-07-2011
20100303760TREATMENT AND/OR PREVENTION OF CANCER AND/OR ARTHRITIS - The invention relates to the use of INSP163 for treatment and/or prevention of cancer and/or musculoskeletal/connective tissue disorder, in particular of lung cancer and/or osteoarthritis. Combinations of INSP163 with an interferon, a TNF antagonist or a further anti-cancer or anti-arthritis agent are also within the present invention.12-02-2010
20110250175TLR7 LIGAND AND USES THEREOF - The present invention provides a TLR7 ligand and its use in therapeutic applications. Specifically, the present application provides a RNA oligonucleotide comprising a G:U wobble base pair in the context of a fully double-stranded structure and its use in treating disease such as viral infections, immune disorders and cancer.10-13-2011
20090010885Methods for Detecting and Treating Autoimmune Disorders - The present disclosure relates to methods for inhibiting an autoimmune disease by administering to a subject a therapeutically effective amount of a composition that increases FOXP3 expression, thereby inhibiting the autoimmune disease. Further disclosed herein are methods for detecting in a subject an autoimmune disease or a predisposition to an autoimmune disease, and methods for assessing the efficacy of a therapy for an autoimmune disease.01-08-2009
20090180985BRIDGED CARBOCYCLIC OXIME HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS - The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof:07-16-2009
20080279819Combinations Therapy for Treatment of Demyelinating Conditions - The present invention provides novel methods and compositions for the treatment and prevention of demyelinating conditions. One demyelinating condition treated by the methods and compositions of the invention is multiple sclerosis. Also treated are symptoms associated with multiple sclerosis.11-13-2008
20080279821ARYLPIPERIDINYL AND ARYLPYRROLIDINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:11-13-2008
20080279820Compositions and Methods for Treating Burns - The present invention provides compositions and methods for treating burns comprising administering to a burn area of a subject in need thereof of a therapeutically effective amount of a composition comprising an anti-cytokine or anti-inflammatory agent or a functional derivative thereof, and a pharmaceutically acceptable excipient.11-13-2008
20080219952Process For the Preparation of Glycosylated Interferon Beta - The present invention relates to a process for the production of interferon beta, and to an interferon beta composition having a unique glycosylation pattern.09-11-2008
20110165122METHOD FOR TARGETED AND SUSTAINED ANTIVIRAL THERAPY - Compounds compositions and methods of modulating the immune response are provided. The method uses fusion proteins of a cytokine and an antibody to potentiate the action of the cytokine.07-07-2011
201101651235' TRIPHOSPHATE OLIGONUCLEOTIDE WITH BLUNT END AND USES THEREOF - The present invention provides an oligonucleotide which is capable of activating RIG-I and inducing an anti-viral, in particular, an IFN, response in cells expressing RIG-I. The present invention further provides an oligonucleotide which is capable of activating RIG-I and which has target gene-silencing activity. The oligonucleotide of the present invention has a double-stranded section of at least 19, preferably at least 21 bp, at least one 5′ triphosphate, and at least one blunt end which bears a 5′ triphosphate. The present invention further provides the use said oligonucleotide for inducing an anti-viral, in particular, an IFN, response in vitro and in vivo. The present invention additionally provides the use of said oligonucleotide for preventing and/or treating diseases or conditions such as infections, tumors/cancers, and immune disorders.07-07-2011
20080253996Use of Sdf-1 for the Treatment and/or Prevention of Neurological Diseases - The invention relates to the use of SDF-1, or of an agonist of SDF-1 activity, for the treatment and/or prevention of a neurological disease.10-16-2008
20110020280PHARMACEUTICAL COMPOSITION FOR TRANSNASAL ADMINISTRATION - By a pharmaceutical composition for nasal administration comprising a hydrophilic bioactive substance and any one of (a) to (c) below, with the proviso that a C-terminal amidated peptide is excluded, a hydrophilic bioactive substance having a low transmucosal absorption capability which has conventionally been able to be administered by only injection can be nasally administered. Such a pharmaceutical composition is useful for improvement of the pain and the inconvenience of patients caused by administration by injection. 01-27-2011
20110135603INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE - The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3Kγ. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.06-09-2011
20110052535COMPOSITIONS FOR TREATING AN INFLAMMATORY AUTOIMMUNE CONDITION - The present invention relates to a medicament comprising human Tr1 cells directed to a human HSP and methods for treating an inflammatory autoimmune condition.03-03-2011
20100322900Treatment of multiple sclerosis with laquinimod - The subject invention provides for methods of reducing the relapse rate and/or reducing the accumulation of physical disability in a relapsing-remitting multiple sclerosis human patient, the method comprising orally administering to the patient a daily dose of 0.6 mg laquinimod.12-23-2010
20110256096Estrogen receptor ligand and/or interferon beta treatment for neurodegenerative diseases - This invention relates generally to novel treatments to prevent neurodegeneration in the central nervous system comprising a therapeutic dosage of an estrogen receptor ligand and/or an immunotherapeutic compound, such as beta-interferon, to ameliorate the effects of the neurodegenerative disease and to stimulate repair.10-20-2011
20080279822Crystalline Polymorphs of a CXC-Chemokine Receptor Ligand - The present invention relates to four distinct crystalline polymorphs of a monohydrate of Compound A having the following chemical structure:11-13-2008
20100196317CYCLIC UNDECAPEPTIDES AND DERIVATIVES AS MULTIPLE SCLEROSIS THERAPIES - A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of a cyclosporin compound.08-05-2010
20100196318Methods of Treating Inflammatory and Autoimmune Diseases with Natalizumab - Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease; and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment. Monitoring for JCV and informing caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of natalizumab therapy.08-05-2010
20090175823METHOD OF TREATING AUTOIMMUNE DISEASES WITH INTERFERON-BETA AND IL-2R ANTAGONIST - Disclosed is a method of administering an interleukin-2 receptor (IL-2R) antagonist to a subject to treat an autoimmune disease. In particular embodiments, the IL-2R antagonist is an anti-IL-2R monoclonal antibody specific for one or more chains of the IL-2R, such as the alpha-chain, for example daclizumab. In other particular embodiments the autoimmune disease is multiple sclerosis. In certain embodiments administration of interferon-beta is combined with administration of an antagonist of the IL-2R to provide significant clinical improvement in a subject with an autoimmune disease.07-09-2009
20090175822C5-SUBSTITUTED, PROLINE-DERIVED, MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof:07-09-2009
20100189686Albumin Fusion Proteins - The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.07-29-2010
20100189687MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS - The present application provides for a compound of Formula IV, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.07-29-2010
20110189131ACTIVE VARIANTS OF THE IL-18 BINDING PROTEIN AND MEDICAL USES THEREOF - The invention relates to active fragments of the IL-18 binding protein, to pharmaceutical compositions comprising such active fragments, and to medical uses thereof.08-04-2011
20100021429CLADRIBINE REGIMEN FOR TREATING MULTIPLE SCLEROSIS - The present invention relates to the use of multiple doses of Cladribine combined with beta interferon for the treatment of multiple sclerosis in patients who are refractory to at least one conventional therapy.01-28-2010
20110097306ORAL FORMULATIONS OF CLADRIBINE - Provided are compositions of cladribine and cyclodextrin which are especially suited for the oral administration of cladribine.04-28-2011
20090208454MODIFIED INTERFERON BETA POLYPEPTIDES AND THEIR USES - Modified interferon beta polypeptides and uses thereof are provided.08-20-2009
20100028298INTERFERON TYPE I SUPPORTING COMPOUNDS - The present invention relates to the use of cyclic peptides, in particular of vioprolides for the treatment and prevention of various diseases, disorders and conditions. In particular, the present invention provides compounds useful in enhancing and/or supporting interferon type I1 like interferon alpha or interferon beta, treatment or prevention of diseases, disorders or conditions. Further, the present invention relates to new pharmaceutical compositions comprising specific cyclic peptides, in particular, vioprolides, and type I interferon and its use in the treatment of various diseases, in particular, in the treatment or prevention of infectious diseases, cancers etc. Finally, the present invention provides methods for preventing or treating diseases, disorders or conditions susceptible to type I interferon treatment or prevention.02-04-2010
20110150833BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS - Compounds useful as Rho kinase inhibitors of formula (1) wherein the variables are as defined herein are provided. Methods of treatment of malconditions mediated by Rho kinase, and methods of preparation of the compounds, are also provided.06-23-2011
20110305669PROCESS FOR THE PREPARATION OF GLYCOSYLATED INTERFERON BETA - The present invention relates to a process for the production of interferon beta, and to an interferon beta composition having a unique glycosylation pattern.12-15-2011
20090087410TREATMENT OF HYPERSENSITIVITY - The present invention relates to a method for inhibiting a hypersensitivity reaction in a subject, wherein said method comprises administering an effective amount of chaperonin (10).04-02-2009
20120177603METHOD FOR THE PURIFICATION OF INTERFERON-B - A method for the production of human glycosylated Interferon-beta (IFN-β) is described, comprising two affinity chromatography steps followed by hydrophobic interaction chromatography step preferably with a subsequent anion exchange chromatography step. IFN-β obtained by the method as described is characterized by a high purity and specific biologically activity, because of which it is particularly suitable for the production of pharmaceutical compositions.07-12-2012
20120039849TETRAHYDROTHIAZOLOPYRIDINE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE - The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3Kγ. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.02-16-2012
20120070416Macrocyclic Proline Derived HCV Serine Protease Inhibitors - The present invention discloses compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof:03-22-2012
20110171176COMPLEMENT ANTAGONISTS AND USES THEREOF - Disclosed are antagonists designed to inhibit or block expression of a mammalian complement such as complement component 6 (C6). The invention has a wide range of uses including use in the preparation of a medicament for the enhancement of nerve regeneration following acute or chronic nerve damage in a mammal. Additional applications include use in the treatment of multiple sclerosis either alone or in combination with another drug.07-14-2011
20120003184SODIUM SALT OF 5-CYCLOPROPYL-2-BENZOIC ACID AS DHODH INHIBITOR - The present disclosure is directed to the sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid, pharmaceutically acceptable solvates thereof, pharmaceutical combinations thereof, and methods of treatment.01-05-2012
20120003183ADDITION SALTS OF TROMETHAMINE WITH AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS - The present disclosure is directed to novel crystalline addition salts of (i) tromethamine with (ii) an azabiphenylaminobenzoic acid derivatives of formula (I), pharmaceutically acceptable solvates thereof, pharmaceutical combinations thereof, and methods of treatment.01-05-2012
20120301429DAC HYP COMPOSITIONS AND METHODS - The present disclosure relates to compositions of daclizumab suitable for subcutaneous administration and methods of manufacturing thereof.11-29-2012
20120009150DIARYL UREAS FOR TREATING VIRUS INFECTIONS - The present invention relates to pharmaceutical compositions for treating virus infections and/or diseases caused by virus infections comprising at least a diaryl urea compound optionally combined with at least one additional therapeutic agent. Useful combinations include e.g. BAY 43-9006 as a diaryl urea compound.01-12-2012
20100239528Treating or Ameliorating a Neuroinflammatory or Demyelinating Disorder with Prolactin and Interferon-Beta - Methods, compositions and kits for treating or ameliorating a disorder associated with neuroinflammation or de-myelination in a mammal are disclosed. Said methods, compositions and kits comprise prolactin, a prolactin-inducing agent, or a variant, analog or functional fragment of prolactin in combination with interferon-β.09-23-2010
20120014918ADDITION SALTS OF AMINES CONTAINING HYDROXYL AND/OR CARBOXYLIC GROUPS WITH AMINO NICOTINIC ACID DERIVATIVES AS DHODH INHIBITORS - The present disclosure is directed to novel water-soluble pharmaceutically acceptable, crystalline addition salts of (i) an amine containing one or more hydroxyl and/or carboxylic groups with (ii) amino nicotinic acid derivatives of formula (I)01-19-2012
20120014916POLYALKYLENE POLYMER COMPOUNDS AND USES THEREOF - The invention relates to novel polyalkylene glycol compounds and methods of using them. In particular, compounds comprising a novel polyethylene glycol conjugate are used alone, or in combination with antiviral agents to treat a viral infection, such as chronic hepatitis C.01-19-2012
20120014915Estriol Therapy for Autoimmune and Neurodegenerative Disease and Disorders - The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, including post-partum auto immune diseases) and more particularly. Most preferably the invention uses estrogens, estranges, estriol or estrogen receptor active agents to prevent or ameliorate clinical symptoms of these ThI-mediated (cell-mediated) autoimmune diseases known to either have an initial onset following the birth of a child or which are exacerbated in patients in the post01-19-2012
20120058083Therapies for Chronic Inflammatory Demyelinating Polyneuropathy Using Interferon-Beta - The present invention provides methods for the treatment, and pharmaceuticals for the use in the treatment, of mammalian subjects having, or at risk of developing, chronic demyelinating neuropathies, e.g., CIDP. The methods involve the administration of IFN-β therapeutics.03-08-2012
20110091422Use of Genetic Markers for Identifying the Response to Interferon Treatment in Multiple Sclerosis Patients - The present invention relates to the use of genetic markers to identify the response to interferon-beta (IFN-beta) treatment in Multiple Sclerosis (MS) patients as well as a method for treating MS patients and kits for genotyping.04-21-2011
20100239529PEG-Interferon-Beta Formulations - The invention relates to a liquid pharmaceutical composition comprising a pegylated IFN-β (PEG-IFN-β), an excipient, a surfactant and a buffer wherein said excipient is a polyol, wherein said surfactant is a non-ionic surfactant and wherein said buffer is a sodium acetate buffer.09-23-2010
20110104116HSA-FREE FORMULATIONS OF INTERFERON-BETA - Stabilized pharmaceutical compositions comprising substantially monomeric interferon-beta (IFN-β) and methods useful in their preparation are provided. The compositions comprise the IFN-β solubilized in a low-ionic-strength formulation that maintains the composition at a pH of about 3.0 to about 5.0. Methods for preparing these compositions, and for increasing solubility of IFN-β in pharmaceutical compositions, are provided.05-05-2011
201000924262-SUBSTITUTED BENZIMIDAZOLES - Inhibitors of RSV replication of formula (I) the addition salts and stereochemically isomeric forms thereof, wherein Q is hydrogen, C1-6alkyl optionally substituted with a heterocycle or Q is C1-6alkyl substituted with both —OR4 and a heterocycle; wherein said heterocycle is oxazolidine, thiazolidine, 1-oxo-thiazolidine, 1,1-dioxothiazolidine, morpholinyl, thiomorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxothiomorpholinyl, hexahydrooxazepine, hexahydro-thiazepine, 1-oxo-hexahydrothiazepine, 1,1-dioxo-hexahydrothiazepine, pyrrolidine, piperidine, homopiperidine, piperazine; which heterocyle may be substituted with 1-2 substituents; each Alk is C1-6alkanediyl; R1 is Ar2 or optionally substituted piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, furanyl, tetrahydro-furanyl, thienyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, isothiazolyl, pyrazolyl, isoxazolyl, oxadiazolyl, quinolinyl, quinoxalinyl, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, pyridopyridyl, naphthiridinyl, 1H-imidazo[4,5-b]pyridinyl, 3H-imidazo[4,5-b]pyridinyl, imidazo[1,2-a]pyridinyl or 2,3-dihydro-1,4-dioxino[2,3-b]pyridyl; R3 is hydroxyC1-6alkyl, C1-6alkoxyC1-6alkyl, cyanoC1-6alkyl, aminocarbonyl-C1-6-alkyl, mono- or di(C1-6alkyl)aminocarbonyl-C1-6-alkyl, carboxyl-C1-6-alkyl, C1-6alkoxycarbonyl-C1-6alkyl; R2 is hydrogen or C1-6alkyl; R3 and R4 are hydrogen, C1-6alkyl, Ar2, Ar2C1-6alkyl, C1-6alkylcarbonyl, Ar2carbonyl, Ar2C1-6alkylcarbonyl, C1-6alkylsulfonyl, aminosulfonyl, Ar1sulfonyl, Ar1C1-6alkylsulfonyl, C1-6alkyloxyC1-6alkyl, aminoC1-6alkyl, mono- or di(C1-6alkyl)-aminoC1-6alkyl, hydroxyC1-6alkyl, aminocarbonylC1-6alkyl, C1-4alkyloxycarbonyl-C1-6alkyl, hydroxycarbonylC1-6alkyl, aminosulfonylC1-6alkyl, Het, Het-C1-6alkyl, Het-carbonyl, Het-sulfonyl, HetC1-6alkylsulfonyl, Het-C1-6alkylcarbonyl; Het is an optionally substituted heterocycle; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I).04-15-2010
201201215413,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO[4,5-D]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF - The invention is directed to 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and pharmaceutical compositions containing them, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds and prodrugs.05-17-2012
20100021428Use Of Gelsolin To Treat Multiple Sclerosis And To Diagnose Neurologic Disease (Stossel) - The invention relates to the use of gelsolin to treat neurologic diseases (e.g., multiple sclerosis) and to the use of gelsolin to diagnose, monitor, and evaluate therapies of neurologic diseases.01-28-2010
20120219524ANTIBODIES THAT BIND COLONY STIMULATING FACTOR 1 RECEPTOR (CSF1R) - Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.08-30-2012
20100172869METHOD FOR TREATING MULTIPLE SCLEROSIS - Methods for treating multiple sclerosis (MS) and clinically isolated syndromes suggestive of MS are provided. The methods comprise administering a therapeutically effective dose of interferon-beta (IFN-beta) to a subject in need thereof, where the dose is administered intramuscularly with a dosing frequency of two- to three-times per week.07-08-2010
201202374802'ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES - The present invention relates to 2′-allene-substituted nucleoside derivatives of the general formula (I):09-20-2012
20090060874BICYCLIC PYRROLIDINE DERIVATIVES - The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:03-05-2009
20090060873Novel synthetic triterpenoids and methods of use in the treatment and prevention of multiple scleroris - The present invention overcomes limitations of the prior art by providing new compounds and methods for the treatment of conditions, such as neurodegenerative diseases (e.g., multiple sclerosis), psychiatric disorders (e.g., psychosis, bipolar disorder, depression, neuropathic pain), conditions involving CNS-mediated chronic pain, spinal cord injuries, and other diseases or injuries.03-05-2009
20090047248TRIAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters or prodrugs thereof:02-19-2009
20120082647INTERFERON-BETA FOR USE AS MONOTHERAPY OR IN COMBINATION WITH OTHER CANCER THERAPIES - This description relates to the use of a polymer-conjugated interferon-beta as monotherapy or in combination with other cancer therapies.04-05-2012
20090016991Rxr Antagonist Treatment Against Multiple Sclerosis - Retinoids with retinoid antagonistic activities, especially Retinoid X Receptor antagonists called RXR antagonists, pharmaceutically acceptable salts and pharmaceutically acceptable esters and amides thereof, have been found to be effective in the treatment of multiple sclerosis, especially by systemic such as oral administration of RXR antagonists.01-15-2009
20110002885METHODS OF USING ISOLATED RECOMBINANT POLYPEPTIDE ANTAGONISTS OF SDF-1 - This invention is generally directed to a recombinant method of producing SDF-1 receptor antagonists. More particularly, the invention is directed to the isolated and/or recombinant polynucleotide sequences encoding analogs of human SDF-1 alpha or beta and, in particular, SDF-1 analogs having the proline at residue position number 2 replaced with a glycine to provide an SDF-1 receptor antagonist. The recombinant method can be used to produce drugs for a variety of therapeutic uses including, but not limited to, treatment of cancer, inhibiting angiogenesis, and hematopoietic cell proliferation.01-06-2011
20110038835ANILIDES AND ANALOGS AS RHO KINASE INHIBITORS - Compounds useful as Rho kinase inhibitors of formula (I): wherein variable are as defined herein are provided. Methods of treatment of malconditions mediated by Rho kinase, and methods of preparation of the compounds, are also provided.02-17-2011
20110044945AGENTS FOR THE TREATMENT OF MULTIPLE SCLEROSIS AND METHODS OF USING SAME - A method of treating Multiple Sclerosis is disclosed. The method comprises administering to the subject a therapeutically effective amount of SDF-1 alpha. An article of manufacture comprising SDF-1 alpha and an anti-Multiple Sclerosis agent is also disclosed.02-24-2011
20120269770Stable Preserved Compositions of Interferon-Beta - Stable preserved compositions of interferon-β and pegylated-interferon-β are described.10-25-2012
20120321590BRIDGED POLYCYCLIC COMPOUNDS - The invention is directed to amides of bicyclic amine compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.12-20-2012
20120328567BIOMARKERS PREDICTIVE OF THERAPEUTIC RESPONSIVENESS TO IFNB AND USES THEREOF - Methods, assays and kits for the identification, assessment and/or treatment of a subject having multiple sclerosis (MS) (e.g., a patient with relapsing-remitting multiple sclerosis (RRMS)) are disclosed.12-27-2012
20120328566ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES - The present invention relates to treatment of neurological diseases such as multiple sclerosis (MS) and Alzheimer's disease, using an estrogen receptor beta (ERβ) ligand in combination with a standard, anti-inflammatory agent.12-27-2012
20100203017Cladribine Regimen for Treating Multiple Sclerosis - The present invention is related to the use of Cladribine for the preparation of a pharmaceutical formulation for the treatment of multiple sclerosis, especially relapsing-remitting multiple sclerosis or early secondary progressive multiple sclerosis, wherein the preparation is to be the orally administered and wherein re-treatments are possible.08-12-2010
20120134959PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES - The invention relates to pyrimidine compounds of the Formula I: or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds.05-31-2012
20110135604ANTIVIRAL COMPOUNDS - The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.06-09-2011
20110158943INTERFERON ALPHA 2B MODIFIED BY POLYETHYLENE GLYCOL, THE PREPARATION AND USE THEREOF - The present invention relates to interferon-α2b modified with Y-shaped branched polyethylene glycol (PEG) at a single Lys residue and the preparation thereof. The peglated IFN-α2b can be used for the preparation of a medicament for treating a disease, e.g. viral infections such as Hepatitis C.06-30-2011
20090214473COMBINATION CHAPERONIN 10 AND BETA-INTERFERON THERAPY FOR MULTIPLE SCLEROSIS - A method of treating multiple sclerosis (MS) is provided which includes the step of administering a pharmaceutically-effective amount of chaperonin 10 and IFN-beta. Also provided are pharmaceutical compositions and a kit for treating MS, which include chaperonin 10 and IFN-beta.08-27-2009
20110274657OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR ANTAGONISTS - The present disclosure relates to oxadiazole derivatives of formula (I) as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the S1P1 receptor.11-10-2011
20120251494CD40 AGONIST ANTIBODY /TYPE 1 INTERFERON SYNERGISTIC ADJUVANT COMBINATION, CONJUGATES CONTAINING AND USE THEREOF AS A THERAPEUTIC TO ENHANCE CELLULAR IMMUNITY - A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided.10-04-2012
20130095069METHOD OF TREATING AUTOIMMUNE DISEASES WITH INTERFERON-BETA AND IL-2R ANTAGONIST - Disclosed is a method of administering an interleukin-2 receptor (IL-2R) antagonist to a subject to treat an autoimmune disease. In particular embodiments, the IL-2R antagonist is an anti-IL-2R monoclonal antibody specific for one or more chains of the IL-2R, such as the alpha-chain, for example daclizumab. In other particular embodiments the autoimmune disease is multiple sclerosis. In certain embodiments administration of interferon-beta is combined with administration of an antagonist of the IL-2R to provide significant clinical improvement in a subject with an autoimmune disease.04-18-2013
20130129679INTERFERON BETA AS ANTIBACTERIAL AGENTS - The present invention describes method of treating bacterial infections, including MRSA. In various embodiments, the methods can use interferon beta, which is found to have antimicrobial activity. In certain embodiments, the interferon beta can be human interferon beta. In other embodiments, the interferon beta can be mouse interferon beta. In further embodiments, the interferon beta can be human interferon beta containing amino acid substitutions to make the human interferon beta more cationic in neutral pH.05-23-2013
20110243893MARKERS FOR DETERMINATION OF PATIENT RESPONSIVENESS - Compositions and methods are provided for prognostic classification of inflammatory diseases, e.g. inflammatory demyelinating disease, patients into subtypes, which subtypes are informative of the patient's need for therapy and responsiveness to a therapy of interest. The patterns of cytokines provides for a signature pattern that can identify patients likely to benefit from therapeutic intervention as well as discriminate patients that have a high probability of responsiveness to a therapy from those that have a low probability of responsiveness. Assessment of this signature pattern thus allows improved methods of care. In one embodiment of the invention, the autoimmune disease is multiple sclerosis or neuromyelitis optica.10-06-2011
20110256097Treatment of Conditions that Increase in Severity and/or Occurrence During One or More Phases of the Menstrual Cycle - Methods are provided for treating a subject for a condition. In accordance with the subject methods, at least a portion of a subject's autonomic nervous system is modulated during at least one predetermined phase of the subject's menstrual cycle to alter the parasympathetic activity/sympathetic activity ratio in a manner that is effective to treat the subject for the condition. The subject methods find use in the treatment of a variety of different conditions, including various disease conditions, that increase in severity and/or occurrence during one or more phases of the menstrual cycle. Also provided are systems and kits for use in practicing the subject methods.10-20-2011
20120276049Methods and compositions for amelioration of autoimmune disease using fusion proteins of anti-dendritic cell receptor antibody to peptide sequences - Compositions that are fusion proteins of antibodies to dendritic cell receptors, exemplified by anti-DEC205 and anti-33D1 antibodies, to peptide sequences that are immunosuppressive or tolerogenic are provided for treatment of autoimmune diseases such as multiple sclerosis. Also provided are pharmaceutical compositions including the fusion proteins, as well as therapeutic methods for administering the fusion proteins.11-01-2012
20100297077NOVEL ARYL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF - The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.11-25-2010
20130156735USE OF THE COMBINATION OF TERIFLUNOMIDE AND INTERFERON BETA FOR TREATING MULTIPLE SCLEROSIS - This invention is related to the use of the combination of teriflunomide and interferon beta thereof, for the preparation of a medicament for use in treating multiple sclerosis.06-20-2013
20120282223Amorphous (5-Fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-Acetic Acid - The invention relates to a stable amorphous form of (5-Fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid and its use in the treatment of conditions mediated by the action of PGD11-08-2012
20120282222Estrogen receptor ligand and/or interferon beta treatment for neurodegenerative diseases - This invention relates generally to novel treatments to prevent neurodegeneration in the central nervous system comprising a therapeutic dosage of an estrogen receptor ligand and/or an immunotherapeutic compound, such as beta-interferon, to ameliorate the effects of the neurodegenerative disease and to stimulate repair.11-08-2012
201103114851,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE - The present disclosure relates to 1, 2, 4 oxadiazole derivatives of formula (I) as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the S1P1 receptors.12-22-2011
20110311484STRAINS OF XENOTROPIC MURINE LEUKEMIA-RELATED VIRUS AND METHODS FOR DETECTION THEREOF - Provided are novel strains of Xenotropic Murine Leukemia Virus-Related Virus (XMRV), or polynucleotides or polypeptides thereof. Identified herein are nucleic acid changes or amino acid changes identified in XMRV strains isolated from subjects. Also provided are methods of detecting such XMRV strains based at least in part on the identified nucleic acid changes or amino acid changes.12-22-2011
20110311483CRTH2 MODULATORS - Compounds of Formulae I-1 to I-9 are disclosed, which are modulators of CRTH2, particularly antagonists of CRTH2, that are useful for treating various disorders, including asthma and respiratory disorders.12-22-2011
20110311482Hepatitis C Virus Inhibitors - Hepatitis C virus inhibitors are disclosed having the general formula:12-22-2011
20120003182GENETIC SEVERITY MARKERS IN MULTIPLE SCLEROSIS - The present invention relates to the use of SNPs in predicting susceptibility and/or severity of Multiple Sclerosis in an individual. The SNPs are located in the introns of the glycosylation enzymes MGAT5 and XYLT1, 3′ of HIF1AN, within introns of MEGF11. FGF14, PDE9A and CDH13 and within desert regions of 4q34 and 17p13.01-05-2012
20130202555TREATMENT OF MULTIPLE SCLEROSIS WITH MASITINIB - The present invention relates to a tyrosine kinase inhibitor or a mast cell inhibitor, and in particular masitinib or a pharmaceutically acceptable salt thereof, for the treatment of human multiple sclerosis.08-08-2013
20090191153OXIMYL MACROCYCLIC DERIVATIVES - The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof:07-30-2009
20130209400PYRAZOLE DERIVATIVES AS JAK INHIBITORS - New pyrazole derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).08-15-2013
20130209401COMPOSITIONS AND METHODS FOR INHIBITING ENTRY OF A HEPATIC VIRUS - The present invention embraces Niemann-Pick C1-like 1 protein antagonists and agents that inhibit hepatic virus infection for use in the prevention and treatment of a hepatic virus infection.08-15-2013

Patent applications in class Beta or fibroblast